Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes
- PMID: 22166985
- PMCID: PMC3281526
- DOI: 10.1210/en.2011-1499
Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes
Abstract
Pancreatic islet α-cell glucagon secretion is critically dependent on pancreatic islet β-cell insulin secretion. Normally, a decrease in the plasma glucose concentration causes a decrease in β-cell insulin secretion that signals an increase in α-cell glucagon secretion during hypoglycemia. In contrast, an increase in the plasma glucose concentration, among other stimuli, causes an increase in β-cell insulin secretion that signals a decrease, or at least no change, in α-cell glucagon secretion after a meal. In absolute endogenous insulin deficiency (i.e. in type 1 diabetes and in advanced type 2 diabetes), however, β-cell failure results in no decrease in β-cell insulin secretion and thus no increase in α-cell glucagon secretion during hypoglycemia and no increase in β-cell insulin secretion and thus an increase in α-cell glucagon secretion after a meal. In type 1 diabetes and advanced type 2 diabetes, the absence of an increment in glucagon secretion, in the setting of an absent decrement in insulin secretion and an attenuated increment in sympathoadrenal activity, in response to falling plasma glucose concentrations plays a key role in the pathogenesis of iatrogenic hypoglycemia. In addition, there is increasing evidence that, in the aggregate, suggests that relative hyperglucagonemia, in the setting of deficient insulin secretion, plays a role in the pathogenesis of hyperglycemia in diabetes. If so, abnormal glucagon secretion is involved in the pathogenesis of both hypoglycemia and hyperglycemia in diabetes.
Figures
References
-
- Cherrington AD. 2001. Control of glucose production in vivo by insulin and glucagon. In: Jefferson LS, Cherrington AD, eds. Handbook of physiology. Section 7: the endocrine system. Vol II: the endocrine pancreas and regulation of metabolism. New York: Oxford University Press; 759–785
-
- Gustavson SM, Chu CA, Nishizawa M, Farmer B, Neal D, Yang Y, Vaughan S, Donahue EP, Flakoll P, Cherrington AD. 2003. Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am J Physiol Endocrinol Metab 285:E534–E544 - PubMed
-
- McGarry JD, Foster DW. 1980. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49:395–420 - PubMed
